FeesSafety
Pluang+

Phase 2 trial shows oral PRI-002 is safe and slows cognitive decline in early Alzheimer's patients.

Company Fundamentals
17 Nov 2026, 17:05 WIB
Globe News Wire
View Source
Bullish
Phase 2 trial shows oral PRI-002 is safe and slows cognitive decline in early Alzheimer's patients.

Priavoid announced topline results from its Phase 2 trial of PRI-002, an oral all-D-peptide for early Alzheimer's disease. While the study did not meet its primary efficacy endpoint at 48 weeks, PRI-002 showed a favorable safety profile and significant slowing of cognitive decline by week 72 in key measures. Preliminary biomarker data support its biological activity. The company plans to present full data in 2027 and continue development of PRI-002 as a potential disease-modifying treatment.

Priavoid's Phase 2 data for oral all-D-peptide PRI-002 in Alzheimer's disease is the subject, with Pluang's health sector market context as of Nov 17, 2026 22:21 WIB: out of 150 priced health-sector US stocks, 37 rose and 110 fell. Notable movers include TNGX at USD 22.70 with a -6.08% change and a typical hold time of 5 days, WGS at USD 48.08 down 5.76% with 100% sell order activity and a 21-day hold time, and UNH at USD 391.20 down 5.05% with 77% buy order activity and a 99-day hold time. The largest decline was -6.08%.

More News

Global metal pipe market to reach $190B by 2035, driven by construction and oil & gas demand.

Global metal pipe market to reach $190B by 2035, driven by construction and oil & gas demand.

The global metal pipe market is projected to grow at a 4.4% CAGR, reaching $190.4 billion by 2035. Growth is fueled by rising demand in construction, real estate, oil & gas, and infrastructure modernization. Technological advances, sustainability eff...

Market News
Bullish
50 minutes ago
Global biotech market hits $2.02T in 2026, set to triple by 2035 amid record deals and strong Q3 growth.

Global biotech market hits $2.02T in 2026, set to triple by 2035 amid record deals and strong Q3 growth.

The global biotechnology market reached a valuation of USD 2.02 trillion in 2026 and is projected to grow to USD 6.34 trillion by 2035, driven by a 13.61% CAGR. Leading companies like Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong thir...

Bullish
50 minutes ago
Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene and City of Hope launch Phase 1 trial for new colorectal cancer combo therapy.

Adagene Inc. and City of Hope have started a Phase 1 clinical trial testing a new combination therapy for metastatic colorectal cancer patients resistant to standard treatments. The trial evaluates two experimental drugs, ivonescimab and muzastotug (...

Others
Bullish
2 hours ago
RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand launches its first mobile game Palazzo Chronicles: Match 3 on Google Play.

RoyaLand Company Ltd. has released its first mobile game, Palazzo Chronicles: Match 3, on the Google Play Store. The free-to-play match-3 puzzle game features over 270 levels where players restore a royal palace set in Risorgimento Italy. This launch...

Others
Bullish
2 hours ago
Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank appoints three leaders to boost commercial banking growth and services.

Provident Bank announced three key leadership appointments to strengthen its Commercial Banking division. Edward Galan will lead Middle Market Lending, Dawn Scocco will manage portfolio and credit risk, and John Maio will head Treasury Management Ser...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App